ライフサイエンスコーパス: retroperitoneal

1 A strong emphasis has been placed on retroperitoneal access, which is inherently more attract

2 th the benefits of endoscopic techniques and retroperitoneal access.

3 stemic mastocytosis were hepatosplenomegaly, retroperitoneal adenopathy, periportal adenopathy, mesen

4 per day for 16 weeks) on gene expression in retroperitoneal adipose and heart tissue from obese, dia

5 erator-activated receptor-gamma decreased in retroperitoneal adipose tissue from obese versus lean mi

6 l had a higher amount of intraperitoneal and retroperitoneal adipose tissue mass.

7 otably, key thermogenic markers in brown and retroperitoneal adipose tissues and skeletal muscle were

8 cency outlining the bladder, consistent with retroperitoneal air.

9 ved in a colon cancer patient with extensive retroperitoneal and cervical metastasis.

10 ated [3H]2-deoxyglucose (2-DG) uptake by the retroperitoneal and epididymal white tissue and IBAT, bu

11 rticularly in regard to performing posterior retroperitoneal and subtotal adrenalectomies.

12 underwent resection of residual mediastinal, retroperitoneal, and inguinal cancer, respectively.

13 -size distributions in epididymal, inguinal, retroperitoneal, and mesenteric fat under both weight ga

14 edictive value of masses of intraperitoneal, retroperitoneal, and subcutaneous abdominal adipose tiss

15 P-2 mRNA by more than 10-fold in epididymal, retroperitoneal, and subcutaneous fat tissue of normal,

16 From January 1981 to September 1995, 2340 retroperitoneal aortoiliac reconstructions were performe

17 sigmoid colon was mobilized by a posterior, retroperitoneal approach and the colon was divided intra

18 The retroperitoneal approach for abdominal aortic reconstruc

19 The retroperitoneal approach has been shown to decrease oper

20 The retroperitoneal approach offers certain physiologic adva

21 The retroperitoneal approach permits direct access to the re

22 al advantages of the extended posterolateral retroperitoneal approach, the authors have expanded its

23 We advocate a thoracoabdominal retroperitoneal approach, which provides safe control of

24 d pyeloplasty can be performed by a trans or retroperitoneal approach.

25 e performed by either a transperitoneal or a retroperitoneal approach.

26 bin drop >/=4 g/dL, intracranial hemorrhage, retroperitoneal bleed, or transfusion) among 99 200 pati

27 ]; P < 0.001) but an increase in the odds of retroperitoneal bleeding (OR, 1.57 [CI, 1.12 to 2.20]; P

28 disseminated histoplasmosis, complicated by retroperitoneal bleeding and leading to death, in a pati

29 eath occurred in the standard of care group (retroperitoneal bleeding, not considered treatment relat

30 access-site bleeding, access-site hematoma, retroperitoneal bleeding, or any vascular complication r

31 small increase in the more serious risk for retroperitoneal bleeding.

32 The stents were found in the retroperitoneal cavity connecting both veins in all anim

33 vein was punctured transvenously through the retroperitoneal cavity.

34 und in sacrococcygeal, gonadal, mediastinal, retroperitoneal, cervicofacial and intracranial location

35 , cystic degeneration, necrosis, hemorrhage, retroperitoneal collaterals, and renal vein thrombosis.

36 A normal retromesenteric-retroperitoneal D3 located between the superior mesenter

37 e the feasibility of US in demonstrating the retroperitoneal D3.

38 cal necrosectomy consisted of video-assisted retroperitoneal debridement or, if not feasible, laparot

39 sive surgery (laparoscopic or video-assisted retroperitoneal debridement, depending on location of co

40 nd effective, including videoscopic-assisted retroperitoneal debridement, laparoscopic transgastric d

41 Retroperitoneal dedifferentiated liposarcoma was associa

42 has had a favorable impact on the extent of retroperitoneal disease and has significantly reduced th

43 In assessing group A patients, the bulk of retroperitoneal disease at presentation had no influence

44 ogic stage II patients with low-volume (pN1) retroperitoneal disease increased significantly (40% bef

45 The incidence of retroperitoneal disease outside the boundaries of five m

46 32%) patients had evidence of extratemplate retroperitoneal disease, depending on the boundaries of

47 f transgastric puncture, balloon dilatation, retroperitoneal drainage, and necrosectomy.

48 No patient had omental or retroperitoneal edema alone.

49 curred alone in 26 (38%) and with omental or retroperitoneal edema in 40 (58%) of the 69 patients wit

50 Mesenteric, omental, and retroperitoneal edema occur commonly in patients with ci

51 nteric edema and the presence of omental and retroperitoneal edema.

52 e called a peri-rectal oncologic gateway for retroperitoneal endoscopic single site surgery (PROGRESS

53 In 6 patients who underwent retroperitoneal exploration, 1-4 SNs were identified usi

54 in all patients using the gamma probe before retroperitoneal exploration.

55 ailable literature suggests that survival of retroperitoneal fasciitis is possible with prompt debrid

56 ctose, leading to SNS activation in IBAT and retroperitoneal fat and enhanced GLUT4 expression.

57 ssion of GLUT4 was more abundant in IBAT and retroperitoneal fat from glucose- and fructose-fed anima

58 nterscapular brown adipose tissue (IBAT) and retroperitoneal fat increased in response to glucose and

59 iated fat that appears to originate from the retroperitoneal fat outside and posterior to the interna

60 Inguinal, epididymal, and retroperitoneal fat pads weighed less in the running tha

61 nuclear proteins from BAT, inguinal fat, and retroperitoneal fat tissue interact with the CRE2 motif

62 alysis was performed using the variations of retroperitoneal fat Ucp1 mRNA expression in progeny of g

63 ympathectomy abolished the GLUT4 response in retroperitoneal fat, but was without effect on GLUT4 in

64 Sharp debridement of the retroperitoneal fat, the right anterior rectus sheath, a

65 with concomitant necrosis of peritoneal and retroperitoneal fat.

66 romosome 19 were linked to Ucp1 induction in retroperitoneal fat.

67 curred in white fat tissues, particularly in retroperitoneal fat.

68 lucose disposal rate than intraperitoneal or retroperitoneal fat; however, NIDDM patients were more i

69 , but increased it in epididymal, though not retroperitoneal, fat.

70 This case report describes a retroperitoneal fetus in fetu and discusses its clinical

71 Simian retroperitoneal fibromatosis (RF) is a vascular fibropro

72 We previously identified retroperitoneal fibromatosis-associated herpesvirus (RFH

73 The complete sequence of retroperitoneal fibromatosis-associated herpesvirus Maca

74 wo closely related macaque homologs of KSHV, retroperitoneal fibromatosis-associated herpesvirus-Maca

75 hout SG lesions (RD-nonSG), and IgG4-related retroperitoneal fibrosis (RF).

76 Idiopathic retroperitoneal fibrosis (RPF) is a rare disease.

77 Idiopathic retroperitoneal fibrosis (RPF), reviewed herein, is a ra

78 dominal periaortitis cases, and a portion of retroperitoneal fibrosis cases are all caused by IgG4-re

79 d in the literature as being associated with retroperitoneal fibrosis include the use of beta-blockin

80 Retroperitoneal fibrosis is a disease process with an un

81 Retroperitoneal fibrosis is a rare disease, typically wi

82 In this study, a case of retroperitoneal fibrosis is reported, in which the patie

83 apy is a potentially effective treatment for retroperitoneal fibrosis that warrants evaluation in ran

84 e patient presented with typical symptoms of retroperitoneal fibrosis, along with some atypical vascu

85 f presumed cardiac involvement of idiopathic retroperitoneal fibrosis, otherwise known as Ormond dise

86 be an effective treatment for patients with retroperitoneal fibrosis.

87 s, inflammatory abdominal aortic aneurysm or retroperitoneal fibrosis.

88 dominal aortic aneurysm or periaortitis, and retroperitoneal fibrosis.

89 ssociation of beta-blocker usage, lupus, and retroperitoneal fibrosis.

90 istletoe sign could be helpful in diagnosing retroperitoneal fibrosis.

91 ndromes and one patient with an IgG4-related retroperitoneal fibrosis.

92 t might be a characteristic manifestation of retroperitoneal fibrosis.

93 stranding, peritumoral fat planes obscured, retroperitoneal fluid (subcapsular vs extracapsular), as

94 s, followed by perinephric fat stranding and retroperitoneal fluid for reviewers 1 and 2, respectivel

95 ed in body weight, fat pad mass (omental and retroperitoneal), food intake, serum insulin, hepatic tr

96 Retroperitoneal ganglioneuroma is a rare bening tumor, g

97 CASE REPORT: We present a case of retroperitoneal ganglioneuroma that mimicked renal mass

98 associated with gangrenous pancreatitis and retroperitoneal gangrene.

99 esent a deceptive case of EC associated with retroperitoneal gas gangrene and emphysematous pancreati

100 perforation in previously reported cases of retroperitoneal gas gangrene.

101 st-PCI was defined as: arterial access site, retroperitoneal, gastrointestinal, or genitourinary blee

102 Retroperitoneal GCT should be treated in a similar fashi

103 T magnetic resonance (MR) neurography-guided retroperitoneal genitofemoral nerve (GFN) blocks are saf

104 Results In 26 subjects, 30 retroperitoneal GFN blocks were performed.

105 a rank order of responsiveness of ovarian > retroperitoneal > subcutaneous.

106 patients to serious complications including retroperitoneal haemorrhage and impaired renal function.

107 nts judged to be unrelated to treatment (one retroperitoneal haemorrhage, one subarachnoid haemorrhag

108 He had a primary retroperitoneal hemangiopericytoma removed in 1982 and w

109 The six most common injuries included retroperitoneal hematoma (n = 13) and injuries in the sp

110 nce, clinical features, and risk factors for retroperitoneal hematoma (RPH) after percutaneous corona

111 At necropsy, a small retroperitoneal hematoma along the stent and minimal int

112 uding pseudoaneurysm, arteriovenous fistula, retroperitoneal hematoma, femoral artery thrombosis, sur

113 computed tomography (CT) in 82 patients with retroperitoneal hemorrhage (n = 24), inflammation (n = 3

114 f the pattern of ecchymosis seen in cases of retroperitoneal hemorrhage.

115 imodal therapeutic concept for abdominal and retroperitoneal high-risk sarcomas, RHT is a treatment o

116 Retroperitoneal histology and RFS did not change over ti

117 Surgical repair was effected through a retroperitoneal incision enabling vascular control.

118 False-negative findings were retroperitoneal injury, bowel injury, and intraperitonea

119 We show that knockdown of CD24 increases retroperitoneal invasion and liver metastasis of pancrea

120 xenograft model, and that BART also prevents retroperitoneal invasion and liver metastasis of pancrea

121 b) inhibition of uPAR inhibits tumor growth, retroperitoneal invasion, and hepatic metastasis of huma

122 without gemcitabine on primary tumor growth, retroperitoneal invasion, and hepatic metastasis.

123 hepatic metastasis and completely inhibited retroperitoneal invasion.

124 C2 LOH in four lymph nodes from a woman with retroperitoneal LAM.

125 esponses occurred in uterine, extremity, and retroperitoneal leiomyosarcoma, osteosarcomas, angiosarc

126 normal smooth muscle and a series of primary retroperitoneal leiomyosarcomas.

127 ce following complete resection of a primary retroperitoneal liposarcoma between July 1982 and Decemb

128 currence after complete resection of primary retroperitoneal liposarcoma is a common clinical problem

129 Of 177 patients with primary retroperitoneal liposarcoma operated on for curative int

130 s used to identify 177 patients with primary retroperitoneal liposarcoma treated between July 1982 an

131 WDLS and DDLS, the majority of patients with retroperitoneal liposarcoma will eventually have recurre

132 s with completely resected locally recurrent retroperitoneal liposarcoma.

133 ction are prognostic for survival in primary retroperitoneal liposarcoma.

134 e in a large series of patients with primary retroperitoneal liposarcoma.

135 dependent prognostic factors for survival in retroperitoneal liposarcoma.

136 Secondary retroperitoneal LN dissection revealed a high number of

137 Secondary retroperitoneal LN dissection was done in 32 of 147 pati

138 I (P < .001), hematoma volume (P = .01), and retroperitoneal location (P = .01) were independently as

139 te physiology score II, hematoma volume, and retroperitoneal location are predictors of short-term ou

140 patients with dedifferentiated histology or retroperitoneal location.

141 patients with primary extremity, truncal, or retroperitoneal LS treated between 1982 and 2005 were id

142 Retroperitoneal lymph node (LN) involvement is common in

143 y patients with disseminated GCTs have large retroperitoneal lymph node (RPLN) metastases that may ca

144 We evaluated men undergoing postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) for NSG

145 ratoma in primary tumor and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specime

146 Some authors recommend postchemotherapy retroperitoneal lymph node dissection (PC-RPLND), wherea

147 han reported in men who have a nerve-sparing retroperitoneal lymph node dissection (RPLND) because mo

148 The relapse rate after primary retroperitoneal lymph node dissection (RPLND) for patien

149 the outcome of patients managed primarily by retroperitoneal lymph node dissection (RPLND) or chemoth

150 r betaHCG, betaHCG more than 100 ng/mL, redo retroperitoneal lymph node dissection (RPLND), and secon

151 needed to facilitate decision making between retroperitoneal lymph node dissection (RPLND), primary c

152 ohort and highlight selective use of primary retroperitoneal lymph node dissection (RPLND).

153 with adjuvant radiotherapy, chemotherapy, or retroperitoneal lymph node dissection (RPLND).

154 Retroperitoneal lymph node dissection also appears to be

155 mmended measuring AFP and hCG shortly before retroperitoneal lymph node dissection and at the start o

156 or clinical stage I testis cancer has led to retroperitoneal lymph node dissection being performed mo

157 Minimally invasive retroperitoneal lymph node dissection carries safety and

158 Retroperitoneal lymph node dissection continues to play

159 interest in surveillance rather than primary retroperitoneal lymph node dissection for clinical stage

160 lk sac tumor and 5% embryonal carcinoma, and retroperitoneal lymph node dissection for clinical stage

161 apy and away from radiation, and the role of retroperitoneal lymph node dissection in disseminated no

162 l clinically relevant studies on the role of retroperitoneal lymph node dissection in early and advan

163 The role of retroperitoneal lymph node dissection in postorchiectomy

164 odified templates, a bilateral nerve-sparing retroperitoneal lymph node dissection is the treatment o

165 Retroperitoneal lymph node dissection remains a prominen

166 chemotherapy-resistant disease ('desperation retroperitoneal lymph node dissection'), although the re

167 3%) of 27 patients initially managed without retroperitoneal lymph node dissection.

168 in approximately 40% of all postchemotherapy retroperitoneal lymph node dissections (PC-RPLND).

169 Modified template retroperitoneal lymph node dissections (RPLND) have beco

170 chemotherapy and five had undergone previous retroperitoneal lymph node dissections (RPLNDs).

171 Patients in arm B (n = 60) had only retroperitoneal lymph node involvement (27 patients [45%

172 greater than 2-cm tumor deposits, as well as retroperitoneal lymph node involvement.

173 iver (n = 6), presacral soft tissue (n = 3), retroperitoneal lymph nodes (n = 2), spleen (n = 2), and

174 uptake in the prostatic bed or in pelvic or retroperitoneal lymph nodes had longer PCa-specific surv

175 emotherapy followed by surgical resection of retroperitoneal lymph nodes that contained metastatic ma

176 e bladder (UBC) metastatic to the pelvic and retroperitoneal lymph nodes was treated with gemcitabine

177 opment in the endometriotic lesion, enlarged retroperitoneal lymph nodes, and immune cells infiltrati

178 ad metastatic adenocarcinoma in the resected retroperitoneal lymph nodes, and none had retroperitonea

179 10% had metastatic carcinoma in the resected retroperitoneal lymph nodes, and none of those patients

180 CT in biopsy of small abdominal, pelvic and retroperitoneal lymph nodes.

181 ons; surveillance, adjuvant chemotherapy, or retroperitoneal lymph-node dissection.

182 managed with surveillance, chemotherapy, or retroperitoneal lymphadenectomy (RPLND) with similar sur

183 In experienced hands, laparoscopic retroperitoneal lymphadenectomy for renal cell cancer is

184 trast, patients with elevated markers before retroperitoneal lymphadenectomy have a high rate of rela

185 rom the addition of a distal gastrectomy and retroperitoneal lymphadenectomy to a pylorus-preserving

186 ddition of a distal gastrectomy and extended retroperitoneal lymphadenectomy to a standard pancreatic

187 arker elevation after orchiectomy and before retroperitoneal lymphadenectomy was a significant indepe

188 andard resection plus distal gastrectomy and retroperitoneal lymphadenectomy).

189 odenectomy (including distal gastrectomy and retroperitoneal lymphadenectomy).

190 andard resection plus distal gastrectomy and retroperitoneal lymphadenectomy).

191 s later, surveillance imaging identified new retroperitoneal lymphadenopathy and a large right pelvic

192 chest/abdomen/pelvis showed no evidence for retroperitoneal lymphadenopathy or distant metastases.

193 ging studies revealed progressive pelvic and retroperitoneal lymphadenopathy, and the patient enrolle

194 Evaluation for abdominopelvic retroperitoneal lymphadenopathy, either with imaging alo

195 en and pelvis showed an 11.6-cm pelvic mass, retroperitoneal lymphadenopathy, right hydronephrosis, a

196 Retroperitoneal lymphatics, cisterna chyli, and thoracic

197 han that for active RPF or malignant RPF and retroperitoneal malignant neoplasm.

198 group I, 25 patients with malignant RPF and retroperitoneal malignant neoplasm; group II, 16 patient

199 Several centers have reported high rates of retroperitoneal margin positivity after pancreaticoduode

200 same patient had a negative PET scan of the retroperitoneal mass but relapsed in that area.

201 med and histopathological examination of the retroperitoneal mass revealed GN.

202 rgical approaches enable excellent access to retroperitoneal masses and synchronous excision of ipsil

203 tratemplate metastasis for men with residual retroperitoneal masses less than 1, 1 to 2, 2 to 5, and

204 Retroperitoneal masses were present in three patients.

205 tho DKO mice had significantly (P<0.01) less retroperitoneal, mesenteric, and epididymal fat accumula

206 nseminomatous germ cell tumor had low-volume retroperitoneal metastases (pathologic stage pN1, 1997 t

207 Retroperitoneal metastases were limited to microscopic n

208 th EC predominance, as 40 (32.0%) of 125 had retroperitoneal metastases, compared with 26 (15.6%) of

209 At the time of surgery, the retroperitoneal metastasis in the pelvis was confirmed.

210 Retroperitoneal necrotizing fasciitis is an uncommon sof

211 Early diagnosis of retroperitoneal necrotizing fasciitis, wide and repeated

212 onal Animal Care and Use Committee approval, retroperitoneal neuroblastomas were established in mice

213 iotherapy and presence of hepatic, lung, and retroperitoneal nodal metastases were found to be indepe

214 On multivariable analysis, prechemotherapy retroperitoneal nodal size (odds ratio [OR], 1.12; 95% C

215 site of EHD affected survival, with portal, retroperitoneal nodes and multiple sites associated with

216 ed retroperitoneal lymph nodes, and none had retroperitoneal nodes as the only site of lymph node inv

217 ph nodes, and none of those patients had the retroperitoneal nodes as the only site of lymph node inv

218 ance imaging (MRI), metastatic spread to the retroperitoneal nodes on the left side was detected only

219 went surgical resection of a gastric GIST; a retroperitoneal, nonfunctional paraganglioma; and a medi

220 inferior vena cava occlusion, and pain from retroperitoneal or bowel penetration.

221 RT for retroperitoneal or pelvic sarcoma is controversial, and

222 etrospectively compare patients with primary retroperitoneal or pelvic sarcoma treated during 2003-20

223 advanced-modality RT to surgery for primary retroperitoneal or pelvic sarcoma was associated with im

224 r than 16 years, had evidence of testicular, retroperitoneal, or mediastinal non-seminomatous germ ce

225 wing dissemination to various peritoneal and retroperitoneal organs including the kidneys.

226 teric venous system without traversal of any retroperitoneal organs or adjacent vasculature.

227 confirm that the needle did not traverse any retroperitoneal organs or vessels.

228 ear-old patient with the third recurrence of retroperitoneal paraganglioma.

229 Retroperitoneal pathology and relapse rates were compare

230 Predictors of retroperitoneal pathology included an increasing serum A

231 Retroperitoneal pathology revealed germ cell cancer in 5

232 Demonstration of normal retromesenteric-retroperitoneal position of D3 on ultrasound (US) can ru

233 fast and highly accurate tool to confirm the retroperitoneal position of D3.

234 procedure, whereas 21 underwent a posterior retroperitoneal procedure via bilateral incisions.

235 The treatments were surveillance only; retroperitoneal radiotherapy (RT); bleomycin, etoposide,

236 those with type 2 to have proximal biliary, retroperitoneal, renal, or salivary disease (60% vs 0; P

237 RECENT FINDINGS: Retroperitoneal robotic surgery has been successfully ap

238 Retroperitoneal robotic surgery is a relatively new tech

239 nt publications and review our experience of retroperitoneal robotic surgery.

240 ng response characteristics in patients with retroperitoneal (RP) WD/DD liposarcoma treated at The Un

241 rointestinal RR, 2.78; 95% CI, 1.25 to 6.18; retroperitoneal RR, 5.87; 95% CI, 1.63 to 21.12; and int

242 Vascular resection and retroperitoneal safety margin status did not affect dise

243 nostic factors for survival in patients with retroperitoneal sarcoma and suggest that patients with l

244 reated surgically for primary, nonmetastatic retroperitoneal sarcoma during 1982 to 2010 were identif

245 The histologic diversity and rarity of retroperitoneal sarcoma has hampered the ability to pred

246 All imaging features suggested a retroperitoneal sarcoma in the pelvic region with metast

247 y sarcomas, the efficacy of radiotherapy for retroperitoneal sarcoma is not established.

248 Radiation therapy for retroperitoneal sarcoma patients is complex because it r

249 istologically documented, localised, primary retroperitoneal sarcoma that was operable and suitable f

250 locally advanced or recurrent rectal cancer, retroperitoneal sarcoma, select gynecologic cancers, and

251 considered as standard of care treatment for retroperitoneal sarcoma.

252 herapy in the care of surgical patients with retroperitoneal sarcoma.

253 bility of preoperative radiation therapy for retroperitoneal sarcoma.

254 nt attempted surgical resection of a primary retroperitoneal sarcoma.

255 dent predictor of DSD, LR, and DR in primary retroperitoneal sarcoma.

256 ths vs. 19 months, P = 0.001) and truncal or retroperitoneal sarcomas (39 months vs. 31 months, P = 0

257 Retroperitoneal sarcomas (RPS) are rare tumors composed

258 ients with localized, potentially resectable retroperitoneal sarcomas (RPS).

259 histories of all patients operated upon for retroperitoneal sarcomas between January 1983 and Decemb

260 Primary retroperitoneal sarcomas in the pelvic region are extrem

261 care for patients with localized, resectable retroperitoneal sarcomas is surgical resection with gros

262 ion margin did not predict local control for retroperitoneal sarcomas or fibrosarcomas.

263 rate for other-than-primary fibrosarcoma and retroperitoneal sarcomas, and independently predict dist

264 e shown little efficacy in the management of retroperitoneal sarcomas, making total surgical extirpat

265 e a significant problem in the management of retroperitoneal sarcomas.

266 to the diagnosis, staging, and management of retroperitoneal sarcomas.

267 ansanal NOTES total mesorectal excision with retroperitoneal sigmoid mobilization and coloanal, side-

268 e sarcoma database carrying the diagnosis of retroperitoneal soft tissue sarcoma who were eligible fo

269 not included in the conventional staging of retroperitoneal soft tissue sarcomas (RPS) is essential

270 Retroperitoneal soft tissue sarcomas are rare tumors est

271 Retroperitoneal soft tissue sarcomas are rare tumors.

272 d with long-term survival after resection of retroperitoneal soft tissue sarcomas.

273 ifty-one patients with plaque-like confluent retroperitoneal soft-tissue masses were divided into thr

274 complete resection (R0, R1) of abdominal and retroperitoneal soft-tissue sarcomas (median diameter 10

275 l violation to determine injury to intra- or retroperitoneal solid organs, bowel, mesentery, vascular

276 rinary bladder and metastatic disease in the retroperitoneal space of the pelvis.

277 After exploration of the retroperitoneal space up to the level of the obliterated

278 on that offers the immediate availability of retroperitoneal staging or cytoreductive surgery if nece

279 nd abdomen ( Fig 2 ) revealed periaortic and retroperitoneal stranding.

280 h direct visualization of the needle and all retroperitoneal structures.

281 Retroperitoneal STS are relatively uncommon and constitu

282 Five hundred patients with retroperitoneal STS were admitted and treated between Ju

283 In this study of patients with retroperitoneal STS, stage at presentation, high histolo

284 ique offer an encouraging outlook on robotic retroperitoneal surgery.

285 wing chemotherapy as well as the appropriate retroperitoneal templates to use in the postchemotherapy

286 without significantly affecting the rate of retroperitoneal teratoma (21% v 22%, respectively; P = .

287 of systemic progression and 22% incidence of retroperitoneal teratoma supports RPLND as the preferred

288 .019), but rates of pathologic stage II and retroperitoneal teratoma were unaffected.

289 epresents the largest series of laparoscopic retroperitoneal triple neurectomies for treatment of ing

290 As a primary retroperitoneal tumor, it constitutes only a small perce

291 either large (>10 cm), high-grade or truncal/retroperitoneal tumors should be treated exclusively at

292 brosis - a cause of pain, bowel obstruction, retroperitoneal vascular constriction and right heart fa

293 tumors by virtue of local invasion into the retroperitoneal vessels in the absence of clinically det

294 Retroperitoneal/visceral (RP/V) tumors have a poorer pro

295 emity sarcomas (34% v 41%) and in those with retroperitoneal/visceral sarcomas (29% v 34%).

296 (71 NeoCT patients and 130 Surg patients) or retroperitoneal/visceral sarcomas (34 NeoCT and 74 Surg)

297 ted in profound reductions in epididymal and retroperitoneal WAT mass, without affecting subcutaneous

298 wnregulation of Ip6k1 in murine inguinal and retroperitoneal white adipose tissue (IWAT and RWAT) dep

299 Retroperitoneal white adipose tissue (rWAT) and subcutan

300 ffect on leptin mRNA in either epididymal or retroperitoneal white adipose tissue (WAT) from beta(3)-